Lee Philip, Lee Kiriam Escobar, Anosike Brenda I
From the Albert Einstein College of Medicine, Bronx, New York.
Division of Pediatric Infectious Disease, Children's Hospital at Montefiore, Bronx, New York.
Pediatr Infect Dis J. 2025 Mar 1;44(3):e81-e84. doi: 10.1097/INF.0000000000004594. Epub 2024 Nov 14.
This study evaluates nirmatrelvir/ritonavir (Paxlovid) in preventing severe coronavirus disease 2019 in adolescents (12-18). Conducted from January 2022 to July 2023, it compared hospital admissions and healthcare visits within 30 days post-treatment. Results showed similar follow-up rates between treated and untreated groups, with slightly more adverse effects in the nirmatrelvir/ritonavir group. Further research is needed to confirm its efficacy in this population.
本研究评估了奈玛特韦/利托那韦（帕罗韦德）在预防青少年（12 - 18岁）严重2019冠状病毒病方面的效果。该研究于2022年1月至2023年7月进行，比较了治疗后30天内的住院情况和医疗就诊情况。结果显示，治疗组和未治疗组的随访率相似，奈玛特韦/利托那韦组的不良反应略多。需要进一步研究以证实其在该人群中的疗效。
